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Abstract
Retinoblastoma (RB) is a rare pediatric cancer commonly diagnosed in patients at a very
young age. New therapies for this disease are emerging that involve some degree of sedation,
requiring anesthesia providers to be involved in their care. Intraarterial chemotherapy (IAC) is
one of these new exciting treatment options and requires general anesthesia. Multiple studies and
case reports have reported a sudden decrease in pulmonary compliance during IAC for RB and
attribute this response to the trigemino-cardiac reflex (TCR). Once this event occurs, patients
experience associated hypoxemia, hypotension, bradycardia, and cardiovascular collapse. A
systematic literature review was aimed at educating the anesthesia provider on the signs and
symptoms, pathophysiology, diagnosis and treatment options for patients with RB as well as
identifying possible risk factors for developing this phenomenon.
Keywords: retinoblastoma, intraarterial chemotherapy, pulmonary compliance
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Anesthetic implications of intraarterial chemotherapy for retinoblastoma
Retinoblastoma (RB) is a rare malignancy and is the most commonly diagnosed ocular
cancer among pediatric patients. It can be a devastating disease that may lead to death if not
treated effectively (Rao & Hanover, 2017). Intraarterial chemotherapy (IAC) is a relatively new
treatment option for RB. It is performed in interventional neuroradiology and requires general
anesthesia with tracheal intubation and muscle relaxation. Patients need to remain completely
still as fluoroscopy is used to guide catheter placement in the ophthalmic artery. During this
procedure, patients may develop a sudden and profound decrease in pulmonary compliance that
can lead to hypoxemia, bradycardia, hypotension and ultimately cardiovascular collapse if not
treated appropriately (Scharoun, Han & Gobin, 2016). In some case reports, this
cardiorespiratory event was referred to as the trigemino-cardiac reflex (TCR). This systematic
literature review will discuss RB and its anesthetic implications, define the TCR, and identify
trends in the literature that may detect which patients may be at risk for developing this
cardiorespiratory event. Finally, this paper will also educate the anesthesia provider on how to
prepare, anticipate, identify and treat the sudden and profound decrease in pulmonary
compliance that can occur during IAC for RB.
Methods
A systematic literature review was performed using PubMed and Cinahl databases. The
following key words were used: intraarterial chemotherapy, retinoblastoma, trigemino-cardiac
reflex, cardiopulmonary reflex, pulmonary compliance, pediatric anesthesia, and anesthesia
outside of the operating room. Articles from 2014-2019 were evaluated for relevance. Two
articles from 2013 were included as they were considered “landmark studies.”
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Literature Review
Pathophysiology
RB is a rare pediatric cancer that results from mutations to specific genes during
development. RB occurs in 1 in every 15,000 to 18,000 live births and represents 3% of all
childhood cancers. The tumor begins in the retina and then extends outwards to surrounding
structures (Rao & Hanover, 2017). Normal ocular anatomy can be seen in Figure 1. A tumor
suppressor gene (RBL) has been identified in association with RB. The RBL gene is located on
chromosome 13 (13q) and loss of function mutations to this gene causes nonsense codons or
frameshifts. These changes cause overwhelming tumor cell growth. RB1 gene deletion syndrome
may also occur. However, it is due to the complete lack of chromosome 13q and leads not only
to RB, but also other neurodevelopment delays as well as varying degrees of physical
abnormalities (Rao & Hanover, 2017).
While the RBL gene is responsible for the majority of cases, this type of cancer can also
be due to a genetic mutation, 30-40% which are heritable and 60-70% which are sporadic. In
what is considered "heritable" RB, there are two genetic mutations that occur that lead to the
disease: 1) mutation of the germ cell, which makes all cells in the body prone to RB and other
cancers, and/or 2) mutation of the retinal cell, which can only result in RB. The mutation of the
retinal cell occurs on the same gene as the mutation of the germ cell, but on the paired
chromosome. Patients with this diagnosis are usually diagnosed within the first month of life. In
sporadic RB both mutations occur in the retinal cell, specifically and is diagnosed around the age
of two (Rao & Hanover, 2017).
All of these mutations cause gene underactivity and create an environment in which
cancer cell proliferation is promoted. Under normal conditions, the cell cycle has certain “check
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points” that either allow the cell to continue to
grow if developing normally or stops cell growth
if there is some sort of malfunction in the cell
structure or genetic coding. When these naturally
occurring “check points” do not function as they
are supposed to, such as in the case with the gene
malfunctions that occur with RB, abnormal cell
proliferation occurs at an uncontrolled rate, and
therefore cancerous tumors develop (Grossman &
Porth, 2014). This is exactly what occurs in
patients with RB, and therefore tumor cells
proliferate.
Signs and Symptoms
RB is usually diagnosed after
significant disease progression has taken
place. It can often go unrecognized by
parents as children do not always have overt
symptoms or exhibit any decline in vision or
health (Almontaser, Ritchie, Madison &
Jabbour, 2018). RB can affect only one or
both eyes and is usually diagnosed by the age
of 18, with 95% of diagnoses before the age
of five (Rao & Hanover, 2017). The most
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common sign of RB is leukocoria, also known as the “white pupillary reflex”. This is most often
first noticed by parents when using flash photography in which the child's pupils appear white.
The second most common feature is strabismus, with other associated symptoms including poor
vision, red painful eye, vitreous hemorrhage, phthisis bulbi, sterile orbital cellulitis, and proptosis
(Rao & Hanover, 2017). The further the progression of the disease, the more overt the symptoms
become.
Once diagnosed, in most cases, RB results
in a uni- or multi-focal, dome-shaped retinal mass
with dilated retinal vessels. The tumor starts as a
small, transparent growth that is entirely
intraretinal. In the retina, RB starts out as small
tumors that are less than 3 mm. These tumors will
then extend into the macula and vitreous body (Rao
& Hanover, 2017.) These structures can be seen in
Figure 1. RB is considered extensive when either
50% of the globe is occupied or it has invaded the
optic nerve, choroid, sclera, orbit, or anterior
chamber. As it grows, the tumor becomes opaque
and white and extends away from the vitreous
cavity or towards it. As the malignancy advances,
clinical manifestations advance to the outside of the
eye. (Rao & Hanover, 2017). Figure 2 shows the
clinical presentation of RB. A) exophytic growth
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pattern with diffuse subretinal fluid; B) endophytic growth pattern with diffuse vitreous seeds,
which are primary or secondary collections of tumor cells that are found in the avascular
vitreous; C) advanced RB with neovascular glaucoma; and D) advanced RB with orbital
cellulitis (Rao & Hanover, 2017). As the disease progresses, symptoms become more obvious
and clinical manifestations more severe.
Diagnosis
Official diagnosis of RB is done through a routine eye exam by an ophthalmologist
usually after leukocoria or other physical symptoms are noticed by parents. The extent of
extraocular extension of RB is then evaluated with the use of imaging, including MRI and CT
scan. Other tests include ultrasound, fluorescein angiography, and optical coherence tomography
(Rao & Hanover, 2017). Pediatric patients do not generally undergo routine eye exams, unless
under these circumstances. They are usually unable to cooperate or tolerate eye these exams or
further imaging without some sort of sedation (Almontaser et al., 2018). Therefore, anesthesia
providers are present for these cases and administer anesthetics ranging from moderate sedation
to general anesthesia.
Once a diagnosis is made and extent of tumor extension is evaluated, the tumor is then
grouped and staged. The grouping system evaluates the extent of tumor size, location, severity,
and presence of subretinal and vitreous seeds. The staging system, however, helps to predict
survival in patients with RB. Favorable outcomes for eye preservation exist for patients deemed
stage 0 & I. While patients who have stage IV are predicted to lose their eye and even their life.
The International Classification of Retinoblastoma (ICRB) was created in 2003 and includes
both grouping and staging (Almontaser et al., 2018). The ICRB is listed in Table 1.
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Treatment
After a diagnosis is made, treatment is aimed at vision optimization, eye salvage, and
survival. Treatment options include intravenous chemotherapy, periocular chemotherapy,
intravitreal chemotherapy, radiation therapy, focal therapy, and IAC (Rao & Hanover, 2017).
Figure 3 depicts the administration of these types of chemotherapy.
Intravenous chemotherapy is a widely used form of chemotherapy and can be seen in
Figure 3. Typically, six rounds of a combination of three drugs are administered: vincristine,
etoposide, and carboplatin. This option has displayed very promising success rates, especially in
less advanced cases. In ICRB groups A, B, and C, intravenous chemotherapy has success rates,
defined as eye salvage, of 100%, 93%, and 90% respectively. In ICRB group D and E tumors,
rates of regression and eye salvage with the standard triple-drug chemotherapy have been less
than ideal. Fifty percent of group D eyes required additional treatments including external beam
radiation therapy or enucleation (Rao & Hanover, 2017). While this is a promising treatment
option for group A, B, and C eyes, effectiveness is less than ideal in group D and E eyes.
Intravenous chemotherapy, however, comes with many side effects. The systemic effects
of agents like vincristine, doxorubicin, carboplatin, and etoposide include nephrotoxicity,
hepatotoxicity, cardiomyopathy, ototoxicity, and myelosuppression. It even puts patients at risk
for developing other types of malignancies, especially leukemias (Monroy et al., 2014). These
side effects can be devastating and often leave patients with secondary life-long medical
conditions.
Intravenous chemotherapy is usually administered via central vein through an indwelling
port catheter or peripherally inserted central catheter. Placement of these lines requires
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anesthesia, from moderate sedation to general anesthesia, and therefore pediatric anesthesia
providers are very much involved in the care of these patients.
Periocular chemotherapy is a treatment option for ICRB group D and E tumors that
also have vitreous seeds. Through this approach, seen in Figure 3, chemotherapeutic agent is
administered via a posterior sub-tendon injection in the quadrant of the eye that is closest to the
vitreous seeds. These patients require a larger
concentration of chemotherapeutic agent locally which
can be achieved by this route on administration.
Periocular chemotherapy achieves rapid levels of
chemotherapeutic agent in the vitreous cavity within
30 minutes at concentrations that are six to ten times
higher than what intravenous chemotherapy may
provide. When used in conjunction with high dose
chemotherapy, this option has led to a 95% eye
salvage rate in group C patients and a 70% eye salvage
rate in group D patients (Rao & Hanover, 2017).
Anesthesia providers are involved in these cases as the
injection requires some degree of sedation or general
anesthesia to ensure that the patient does not move and that the chemotherapeutic agent is not
inadvertently injected in the wrong space.
Intravitreal chemotherapy seen in Figure 3, is also a good option for patients who
present with vitreous seeds. This method injects chemotherapeutic agent directly into the
vitreous cavity, instead of the quadrant around it. Because of their lack of blood supply, vitreal
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seeds can be very resistant to intravenous chemotherapy. Ineffective chemotherapeutic
concentration in the vitreous cavity can result in persistent vitreous seeds, making intravitreal
chemotherapy the desired treatment route. Melphalan is the chemotherapeutic agent used in this
technique. With its use, vitreous seed regression from 85-100% has been reported with
associated globe salvage in 80-100% of eyes (Rao & Hanover, 2017). This procedure, however,
is painful and requires some degree of sedation or general anesthesia.
Radiation therapy is also an effective, as well as a potentially curative, treatment option
because RB is a highly radiosensitive tumor. It was once the primary modality of treatment for
RB, but it was associated with too many side effects. These include cataract formation,
inflammation of the cornea or conjunctiva, retinopathy, and bleeding (Rao & Hanover, 2017).
These structures can be seen in Figure 1. Radiation is now only used in refractory cases of RB
where intravenous chemotherapy has been unsuccessful or in multimodal treatment modalities,
as it can shrink tumor size and make other treatments more successful (Rao & Hanover, 2017).
Patients require general anesthesia for this type of treatment, as pediatric patients are unable to
remain still enough for the duration of the procedure. Therefore, anesthesia providers are
essential in their care.
Focal therapy includes cryotherapy, transpupillary thermotherapy, and laser therapy.
These procedures allow for targeted therapy of smaller tumors, using probes or lasers that are
able to kill the malignant cells. These options are usually used after tumor size has decreased
after two to three cycles of chemotherapy or for treatment of small recurrent tumors or subretinal
seeds (Rao & Hanover, 2017). These cases also require general anesthesia because they are
painful, and the patient must remain completely still.
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Enucleation, or the surgical removal of the eye, is the oldest form of treatment for RB. It
best used for unilateral disease in which the patient has experienced complete loss of vision. This
can completely remove all of the malignant tumors and immediately cure the patient. However,
this is now only indicated in advanced cases (Rao & Hanover, 2017). While this is not as
commonly performed, as other treatment options have been effective in globe salvage, when it is
done the patient must be under general anesthesia.
Intraarterial Chemotherapy (IAC)
Intraarterial chemotherapy is a relatively new procedure that is used as a primary
treatment of advanced RB or as a secondary treatment in recurrent cases. It has previously been
described as selective ophthalmic artery chemotherapy or chemosurgery and is performed under
general anesthesia. Using a sterile technique, a catheter is placed in the femoral artery and
advanced through the ipsilateral internal carotid artery. The arterial anatomy is visualized with
angiography and the catheter is then advanced into the ostium of the ophthalmic artery
(Almontaser et al., 2018). It is there where the chemotherapeutic agent is then injected, as can be
seen in Figure 4. This allows for selective administration of the chemotherapeutic agent as close
to the malignancy as possible.
IAC was first used in the 1950s but is now rapidly becoming a popular treatment option
for RB. It is particularly useful for advanced stage D and E RB and recurrent RB following
intravenous chemotherapy. This type of delivery of chemotherapeutic agent minimizes systemic
toxicity that occurs with intravenous chemotherapy. This is not only because a smaller dose is
given but also because the selective administration decreases amount systemically absorbed
(Almontaser et al., 2018). Melphalan and topotecan are the chemotherapeutic agents of choice.
Melphalan is a cytotoxic nitrogen mustard derivative alkylating agent that inhibits both DNA and
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RNA synthesis and topotecan is a topoisomerase
inhibitor that prevents rapidly diving cells from
repairing DNA damage (Almontaser et al., 2018). The
specific chemotherapeutic agent used may vary from
institution to institution and provider preference.
The efficacy of IAC, however, is largely due to
a multidisciplinary approach. Patients with RB
undergoing this type of treatment require frequent
trips to and evaluations from pediatric oncologists,
ophthalmologists, interventional neuroradiologists,
nurse practitioners, and anesthesia providers,
including nurse anesthetists. It is important that there is an open line of communication among
all providers involved, particularly during the procedure itself, to ensure both safe delivery of the
chemotherapeutic agent and proper care of the patient pre, intra, and post procedure. Any
pertinent information regarding the patient’s care should be well documented. Patients will
normally receive three treatments within 3- 4-week intervals. Some patients may require as many
as six treatments to eradicate the entire tumor (Knight, Stiffler, Nixon & Lajoie, 2017).
Information from all providers should be readily available to their multidisciplinary colleagues.
This is often attainable through the use of electronic medical records.
Anesthesia outside of the operating room
IAC is performed outside of the operating room in interventional neuroradiology. When
anesthesia is administered in settings outside of the-operating room, anesthesia providers are
faced with unique challenges that impact patient safety and care. For several reasons, patients
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under anesthesia in these settings are more likely to suffer from adverse events due to poor
monitoring. Older anesthesia equipment is often found in these locations and machinery used to
create images to guide the proceduralist surrounds the patient (Landrigan-Ossar & McClain,
2014). This forces the anesthesia provider to be further away from the patient than they normally
would be in the operating room and creates field avoidance. Communication between the
anesthesia provider and the proceduralist of upmost concern to ensure the safety of the patient.
In most pediatric hospitals with large caseloads, 30%-40% of cases are performed in nonoperating room anesthesia venues (Nelson & Bailey, 2017). Adverse events may occur in these
settings that anesthesia providers must be able to anticipate and treat. Contrast media is often
administered in these procedure areas and patients may develop reactions to this agent.
Anaphylactoid reactions to contrast media usually occur within five minutes of exposure but can
also occur within one hour. Patients will present with symptoms, including bronchospasm,
urticaria, and cardiac instability. Patients at risk for allergic reactions to contrast dye include
those with asthma, ectopic tendencies, and history of reactions to contrast dye (Nelson & Bailey,
2017). The anesthesia provider should have all medications to treat such a reaction available to
him or her in interventional radiology, including epinephrine and intravenous fluids.
Efficacy of intraarterial chemotherapy
The side effects of intravenous chemotherapy include neutropenia, deafness, infection,
and secondary leukemia. Because IAC is selectively administered to the ophthalmic artery, large
amounts of chemotherapeutic agent do not enter systemic circulation, and therefore these
unfortunate side effects do not occur. Selective administration also allows the chemotherapeutic
agent to target the tumor directly. For these reasons, and to maximize the effectiveness of the
chemotherapeutic agent, IAC is being performed at an increasing frequency (Scharoun, Han, &

ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO

14

Gobin, 2016). However, it is important to evaluate whether or not IAC is just as effective as
intravenous chemotherapy for RB.
A meta-analysis by Chen et al. (2018) compared the efficacy of IAC to intravenous
chemotherapy for RB. The authors found there was no statistical difference in globe salvage and
overall success rate—defined as the avoidance of external beam radiation therapy or enucleation
in patients with group A, B, C, and E eyes. However, patients with group D eyes who received
IAC had significantly higher globe salvage rates compared to those who received intravenous
chemotherapy. There was also a significantly higher rate of globe salvage in stage IV and V eyes
among those who received IAC compared to intravenous chemotherapy, with no real difference
in among stage I-III eyes. Between the two groups, there was no difference in tumor recurrence
or metastasis rates but there was a higher overall success rate in IAC eyes compared to
intravenous chemotherapy (Chen et al., 2018). This is especially encouraging for patients with
advanced RB.
In a retrospective interventional case series by Shields et al. (2014), IAC for RB was
analyzed as a primary and secondary treatment option after intravenous chemotherapy for
patients with RB. This study examined a total of 70 eyes in 67 patients with a mean age of 30
months. Each patient received melphalan, with the addition of topotecan and/or carboplatin as
necessary. During their follow up, each patient was assessed for regression of the solid tumor,
subretinal seeds, vitreous seeds, and subretinal fluid. The authors found that globe salvage was
achieved in 72% of eyes that were treated with primary IAC and 62% of eyes treated with
secondary IAC (Shields et al., 2014). Eyes that were found to have failed treatment had an
extensive recurrence of subretinal or vitreous seeds upon examination. Patients who received
IAC as a secondary treatment option had all either failed intravenous chemotherapy or were
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facing enucleation as a treatment option. Interestingly, there was no significant difference in
tumor recurrence found between IAC and intravenous chemotherapy.
These results support the conclusion that IAC can be an effective treatment option for
patients, both as a primary and secondary option. The results discussed by Chen et al. (2018) is
similar to those by Shields et al. (2014), as both authors found higher success rates associated
with IAC compared to intravenous chemotherapy. Patients may benefit from IAC, not only
because of its successful outcome, but also because it is not associated with the same systemic
side effects that accompany intravenous chemotherapy.
Efficacy in young children
RB is most frequently diagnosed in children less than 2 years. It may even be present at
birth and require treatment at a very young age (Grossman & Porth, 2014). This makes it prudent
to evaluate if IAC is a treatment option for children this young. In a retrospective case study by
Chen et al. (2016), IAC was found to be effective in children with RB under the age of 3 months.
The authors studied 10 patients with a mean age of 10.4 weeks who had a total of 28 collective
procedures. One procedure was canceled after the patient developed an internal carotid artery
spasm mid procedure. Of the 27 successful procedures, after a follow up of 28.3 months, tumor
regression was found in 12 out of 13 eyes, all patients were alive, and none of them had
developed metastatic disease (Chen et al., 2016). This is a relatively short follow up period, so it
may not provide support for positive long-term outcomes and unfortunately, there are no other
studies that evaluate IAC for RB in this age group. Furthermore, like most pediatric studies, there
was no control group. Nonetheless, these results support that IAC is a feasible option even for
children younger than 3 months old.
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However, not all patients with primary indications for IAC can actually receive it. In a
literature review by Manjandavida, Stathopoulos, Zhang, Hanovar, and Shields (2019), the
following are listed as contraindications: 1) patients with neovascular glaucoma, orbital cellulitis,
hyphema or blood in the anterior chamber of the eye, 2) evidence of optic nerve, scleral, orbital
or extraocular extension, 3) trilateral RB, 4) systemic metastasis, 5) tumors that may benefit from
transpupillary cryotherapy, and/or intravitreous chemotherapy.
Pediatric anesthesia for IAC for RB
Patients require general anesthesia with endotracheal intubation and muscle relaxation to
undergo IAC as they must remain completely still as the neuroradiologist guides a catheter into
their ophthalmic artery under fluoroscopic visualization. Scharoun et al. (2016) discusses the
anesthetic techniques used by anesthesia providers at Weil Cornell Medical Center in New York,
New York. General anesthesia can be maintained with volatile anesthetic and patients are
mechanically ventilated using pressure control ventilation. Most importantly, the anesthesia
provider must ensure complete immobility of the patient during catheter manipulations by the
proceduralist. After intubation, oxymetazoline, a potent vasoconstrictor, is sprayed into the nare
ipsilateral to the tumor. This causes constriction of vessels in the nose, to ensure that the
chemotherapeutic agent stays in the ophthalmic artery and does not pass into collateral
circulation. Dexamethasone is given to prevent periorbital edema if two chemotherapeutic agents
are administered. Heparin is then administered by the anesthesia provier after the femoral
catheter is placed by the proceduralist.
Once the procedure is completed, dexmedetomidine may be given after the femoral
catheter is removed. The patient needs to remain supine without bending his or her leg to prevent
hematoma formation over the femoral cannula site. Dexmedetomidine can be an excellent
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sedative for this as it preserves respiration, unlike opioids which depress respirations. Muscle
relaxation reversal should then be administered. Patients are then extubated and transported to
PACU (Scharoun et al., 2016). Anesthesia providers should bring emergency medications and
supplies for reintubation during transport if PACU is not in close proximity to interventional
radiology.
Complications of IAC
The concept of delivering a chemotherapeutic agent through the ophthalmic artery to
target the tumor is to limit the amount of agent delivered systemically. The previously discussed
side effects associated with intravenous chemotherapy has pushed the new interest in
implementing IAC as a primary treatment for RB (Monroy et al., 2014). However, IAC, like all
RB treatments, is not a benign procedure and comes with its own effects and complications.
The intraocular complications with IAC discussed by Monroy et al. (2014), include
ophthalmic artery thrombosis, retinal and vitreous hemorrhages, enucleation, orbital edema,
retinal detachment, third cranial nerve palsy, and retinal pigment changes. The extraocular
complications include transient femoral artery occlusion due to thrombus at the catheter insertion
site and periocular erythema. There have also been reports of reversible cerebral
vasoconstriction, but this may have been due to other pharmacologic agents administered during
the procedure, including oxymetazoline, mydriatics that contain phenylephrine, and albuterol.
Despite its occurrence, no permanent sequelae have been reported from cerebral
vasoconstriction. The most serious and pertinent extraocular complication reported by Monroy et
al. (2014) is the transient hemodynamic instability and abrupt decrease in ventilation associated
with ophthalmic artery cannulation. This cardiorespiratory event is the most important IAC side
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effect for anesthesia providers to be aware of, as they need to be able to identify and treat it if it
occurs.
Decreased Pulmonary Compliance During IAC for RB
When undergoing IAC for RB, patients may experience a sudden and profound decrease
in pulmonary compliance. Patients become difficult to ventilate and develop hypoxemia very
rapidly. Following this decrease in compliance, patients experience hemodynamic changes that
may lead to adverse outcomes, including death, if not treated appropriately (Scharoun et al.,
2016.). Pediatric respiratory physiology may contribute to the sudden and profound
cardiovascular manifestations.
Pediatric Vulnerability to Hypoxia
According to Hines & Marshall (2018), there are very important physiological
differences between the adult and pediatric respiratory systems that make pediatric patients
extremely vulnerable to life threatening problems if a decrease pulmonary compliance occurs.
First, a pediatric patient’s oxygen consumption is two times greater than an adult on a per
kilogram basis. This contributes to a rapid onset of hypoxemia when ventilation is compromised.
Second, pediatric patients have higher compliance of their chest wall and lung parenchyma. This
is especially true in newborns and predisposes them to alveolar collapse. Chest wall compliance
is higher in the newborn because there is less ossification of their ribcage. This means that at the
end of exhalation, the “spring” of the chest wall pulling outward to create the negative pressure
that begins inhalation, is much weaker in a child than an adult. This causes a child’s functional
residual capacity, which is the volume of air in the lung at the end of passive exhalation, to be
much closer to closing capacity, which is the volume in the lungs at which the respiratory
bronchioles collapse (Bhalla, Khemani, & Newth, 2017). Therefore, at the end of expiration,
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small airways of the lung collapse and alveoli are not ventilated. This leads to a ventilation to
perfusion mismatch and results in hypoxemia very quickly. Adults, however, do have excellent
elasticity of their chest wall, and therefore and increased functional residual capacity compared
to an infant or a child (Hines & Marshall, 2018). Extensive knowledge of pediatric respiratory
physiology compared to that of the adult is crucial for pediatric anesthesia providers in providing
safe anesthetics.
Presentation of Decreased Pulmonary Compliance
In a case report by Scharoun et al. (2016), the authors present a 2-year-old boy
undergoing IAC for RB. The patient was placed under general anesthesia with muscle relaxation
and mechanical ventilation. The femoral artery was cannulated, and the catheter advanced
toward the internal carotid artery, the catheter was then further advanced to the orifice of the
ophthalmic artery. This can be identified in Figure 4. At this time, the anesthesia provider
noticed a sudden drop in tidal volume by 75%. Upon auscultation, there is no wheezing
appreciated. Albuterol, however, was still administered. There was little improvement in tidal
volume and the patient began to desaturate. The anesthesia provider then hand ventilated the
patient, and after 3 minutes his tidal volumes began to recover. However, the patient then
becomes bradycardic and hypotensive requiring epinephrine. After several doses, as well as
crystalloid fluid administration for blood pressure support, the patient stabilized. The procedure
continues, the patient is extubated, and recovered in the PACU unremarkably.
This cardiopulmonary event occurs in as much as 29% of IAC cases, despite the level of
anesthesia or muscle relaxation (Scharoun et al., 2016). The phenomenon even occurs before
anything is injected into the ophthalmic artery, including saline, contrast, or chemotherapeutic
agent. It is always abrupt and is related to the initial positioning of the catheter in the internal
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carotid artery or the ophthalmic artery. Tidal volumes will decrease, and patients will quickly
desaturate due to the normal pediatric lung physiology that was discussed earlier. This may lead
to bradycardia, hypotension, and cardiovascular collapse (Scharoun et al., 2016). This event must
be quickly identified by the anesthesia provider and treated appropriately.
Risk Factors for Developing a Decrease in Pulmonary Compliance During IAC for RB
As this is now a well-known occurrence with IAC, the question remains—who is at risk
and can the depth of anesthetic effect its occurrence? In a retrospective study by Phillips et al.
(2013), a total of 52 patients underwent a combined 143 rounds of intra-arterial chemotherapy.
Each patient received super selective ophthalmic artery chemotherapy using a standard protocol
for general anesthesia, ophthalmic artery catheterization, and pulsed infusion of melphalan as the
chemotherapeutic agent. All patients were intubated and received volatile anesthetic with muscle
paralysis. Patients who required treatment intraoperatively to maintain cardiac and respiratory
stability were considered to have had an adverse reaction.
Adverse reactions occurred in 35 of the procedures, or 24% of cases (Phillips et al.,
2013.) This finding is similar to the occurrence of 29% of cases as cited by Scharoun et al.
(2016). All of the documented reactions occurred during the second or subsequent
catheterization procedure and consisted of hypoxia, reduced lung compliance, systemic
hypotension, and/or bradycardia. Out of the 143 procedures, only one was abandoned due to
hemodynamic instability.
Two patients were discussed specifically by Phillips et al. (2013). In the case of a 15month-old child weighting 11 kg, undergoing their second intraarterial chemotherapy procedure,
immediately after microcatheter was flushed with 0.9% normal saline the patient experienced a
40% decrease in tidal volume from 130 mL to 70 mL. Following this decrease in lung
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compliance the patient’s blood pressure decreased from 80/50 (58) mmHg to a minimum of
43/16 (25) mmHg. Additionally, the heart rate decreased from 160 to 141 bpm. The second
patient was a six-year-old child weighing 25 kg undergoing their fifth procedure, immediately
upon insertion of the microcatheter into the ophthalmic artery, the patient’s tidal volume
decreased from 247 to 22 mL—a 90% decrease. Following this event, the patient experienced a
decrease in blood pressure from 92/42 (57) mmHg to a nadir of 52/24 (32) mmHg (Phillips et al.,
2013). Specific end-tidal CO2 and peak airway pressure readings were not discussed in these
cases, but this illustrates how drastic the hemodynamic changes can be during this procedure
upon catheter insertion and manipulation.
Phillips et al. (2013) concluded that: 1) The clinical signs present in these patients are
believed to be an autonomic reflex, similar to the TCR or oculocardiac reflex. 2) All of the
documented reactions occurred during the second or subsequent procedures. This means that
patients may become sensitized during initial procedures and then the phenomenon is evoked
with subsequent procedures. 3) Finally, atropine does not alter the incidence or severity of these
reactions. 4) These reactions are life-threatening.
Data from other studies, however, have countered the conclusion that patients become
sensitized and only experience this autonomic respiratory compromise on subsequent
procedures. In a retrospective study by Kato et al. (2014), 122 patients undergoing a total of 468
procedures were studied. Intraoperative peak inspiratory pressure, positive end-expiratory
pressure, tidal volume, oxygen saturation, and end-tidal carbon dioxide were analyzed. Any
change in compliance, decrease in end-tidal carbon dioxide, and clinical outcomes were
assessed. Compliance was defined as (∆ volume/∆ pressure) and computed as tidal volume/
(peak inspiratory pressure- positive end expiratory pressure). Out of the entire subject
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population, 64% experienced a severe compliance event which was defined as a decrease in lung
compliance of 40% (Kato et al., 2014). This means that if a 20 kg child had a normal tidal
volume of 120-180 mL (6-8 ml/kg), their tidal volume would drop to as low as 72-108 mL. In
the group of patients that experienced a severe respiratory compliance event, 20% experienced
oxygen desaturation below 90%. Six of these patients experienced desaturation below 60%.
Similarly, a sudden drop of end-tidal CO2 by 30% occurred in 34% of patients in this subset
(Kato et al., 2014). These are very dramatic hemodynamic changes that would be of upmost
concern to the anesthesia provider.
Out of the 122 patients in this study, 27% experienced this significant decrease in
compliance during their first exposure and 73% experienced the event in a subsequent case. Out
of a subset of 94 patients who had their first and subsequent procedures identified, 67%
experienced at least one severe respiratory event. Of this 67%, 18% of patients experienced a
decrease in compliance during their first procedure (Kato et al., 2014). While the first case
incidence is much smaller than subsequent case incidence, this finding rebuttals Phillips et al.
(2013) conclusion that patients become sensitized to the phenomenon after their first procedure.
Kato et al. (2013) also found that the respiratory compromise is abrupt and always temporarily
related to the initial positioning of the catheter in the internal carotid artery or the ophthalmic
artery. This was found to be the case in every procedure where a respiratory event occurred.
The authors concluded that occurrence of a cardiopulmonary events during the first
procedure is not predictive of it reoccurring in subsequent procedures. However, these events
occur at a predictable stage of the procedure and are self-limiting (Kato et al., 2014). This allows
the anesthesia provider to be prepared for when a decrease in compliance does occur so they can
properly manage it. There should always be clear and open communication between the
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anesthesia provider and neuroradiologist, so when this event does occur, the neuroradiologist can
be notified and pause catheter manipulations until the problem resolves. Patients should
immediately be placed on 100% oxygen and hand ventilated by the anesthesia provider (Kato et
al., 2014). The authors also suggest that this most likely occurs due to a vascular to pulmonary
reflex, which has not been described yet. While other reports suggest it is due to the oculocardiac reflex or trigemino-cardiac reflex, Kato et al. (2014) disagrees.
A retrospective study by Harris & Gaynor (2014) described what they believe is the TCR
occurrence in patients undergoing IAC for RB and the objective change in compliance and vital
signs experienced by those with a positive TCR. Harris & Gaynor (2014) studied 49 patients who
underwent a collective 199 procedures. The authors define a positive TCR as the presentation of
two of the following clinical features: 1) drop in systolic, diastolic, and/or mean blood pressure
by 20% or greater, 2) a drop in pulse oximetry reading of 20% or greater, 3) a decrease in endtidal carbon dioxide measurement of 20% or greater, indicative of a severe decrease in
ventilation related to perfusion, and 4) an increase in peak inspiratory pressure of 20% or greater.
Harris & Gaynor (2014) found a total of 28 TCR events occurred in 18 out of 49 patents
undergoing IAC for RB. In 21 of these cases, the TCR occurred during angiography of the
ophthalmic artery and in seven cases it occurred during flushing or infusion through the catheter.
The TCR did not occur during insertion of the catheter into the internal carotid artery or
cavernous sinus, but only during microcatheter insertion into the ophthalmic artery. Only one of
the TCR events was prolonged as it lasted three minutes and the procedure was aborted. All
other cases were transient, and the procedure was able to continue after the stabilization of vital
signs. Out of the 28 cases, seven received one dose of phenylephrine (1 mcg/kg) to support their
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blood pressure and two patients received epinephrine (1 mcg/kg), not only to support blood
pressure but to also produce bronchodilation (Harris & Gaynor, 2014).
This study found that among all cases with a positive TCR, 85.7% experienced a rise in
peak inspiratory pressure, 75% experienced a decrease in their end-tidal carbon dioxide, and
64.3% experienced a decrease in their systolic blood pressure. The average rise in peak
inspiratory pressure among all cases was 83.3% (Harris & Gaynor, 2014). This means that if a
patient had a normal peak inspiratory pressure of 18 cm H20, then an 83.3% increase would
calculate to be 33 cm H20. This is a notable increase that would be concerning to anesthesia
providers, especially if the patient was paralyzed, not experiencing a change in position, and not
coughing. The average drop in end-tidal CO2 among all cases was by 37.4% (Harris & Gaynor,
2014). This means that a normal reading of 40 mmHg would decrease to 25 mmHg. This would
also be very concerning to anesthesia providers as it indicates a severe decrease in perfusion or
ventilation. Finally, systolic blood pressure decreased by an average of 26.4% (Harris & Gaynor,
2014). To put this into context, a normal systolic blood pressure in a 5-year-old would be 100
mmHg. Of course, under general anesthesia, it may be lower, but a 26.4% decrease from a
systolic blood pressure reading of 100 mmHg would be 74 mmHg. Also, a very concerning sign
for an anesthesia provider.
These studies tell the reader four things. First, a decrease in pulmonary compliance may
occur during IAC in 24-29% of cases. Second, all patients undergoing IAC for RB are at risk of
this event, whether it’s the patients first or subsequent treatment. Third, the timing of the event is
predictable, and will most likely occur during cannulation of the ophthalmic artery. Fourth, this
event is usually transient, but emergency medications, including phenylephrine and epinephrine
should be readily available.
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Trigemino-cardiac Reflex
As the trigemino-cardiac reflex (TCR) and the oculo-cardiac reflex have both been
mentioned in studies and publications describing the pulmonary compromise in patients
undergoing IAC for RB, it is important to discuss and define the reflexes. In an article by
Meuwly et. al (2017), the authors' goal was to improve the definition of the trigemino-cardiac
reflex. They found that the TCR is triggered by a physical and/or chemical stimulation of any
part or branch or the fifth cranial nerve, also known as the trigeminal nerve. Once these nerves
are activated, an afferent signal is sent to the sensory nucleus of the trigeminal nerve, which is
located on the floor of the fourth ventricle. The afferent pathway is connected to the efferent
pathway via the reticular formation. The efferent premotor neurons are located in the nucleus
ambiguous and the dorsal motor nucleus of the vagus nerve. These fibers activate the
cardioinhibitory parasympathetic fibers which cause the clinical symptoms.
A positive TCR is defined as a sudden drop in heart rate and mean arterial blood
pressure. The authors defined the TCR as having two major (plausibility and reversibility) and
two minor (repetition and prevention) criteria. There has to be a direct link of time and action
between stimulation and clinical manifestations and termination of the stimulus should also cease
the manifestations (Meuwly et. al, 2017). The minor criteria suggest that the reflex should occur
every time the stimulus is repeated. Due to ethical reasons, this is not something that can be done
in every TCR case.
Chowdhury & Schaller (2016) define the TCR as a sudden onset of bradycardia with
associated hypotension, apnea or gastric hypermotility during stimulation of any of the sensory

ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO

26

branches of the trigeminal, or fifth cranial nerve. The decrease in heart rate and blood pressure
must be more than 20% from baseline and must be due to manipulation of the trigeminal nerve
during surgery. Symptoms are transient when stimulation is removed (Chowdhury & Schaller,
2016). The authors presented four cases in which they believe the symptoms exhibited by the
patient were due to the TCR. Only two of the cases will be included in this paper, due to a lack
of relevance in the remaining cases. Neither of the cases that will be presented was due to IAC,
but for this paper, the role of the TCR in their outcomes will be discussed.
The first two cases presented by Chowdhury & Schaller (2016) identify nasal packing to
treat epistaxis as the precipitating factor before developing bradycardia, respiratory distress with
a concomitant decrease in oxygen saturation, and hypotension. Both patients were intubated and
provided advanced cardiac life support. Both patients, unfortunately, died as a result.
Interestingly, nasal packings were not removed during resuscitation. This highlights that the TCR
is not just limited to direct surgical stimulation and can result from indirect manipulation of the
trigeminal nerve (Chowdhury & Schaller, 2016). Either direct or indirect, the TCR can be
devastating if not treated appropriately, leading to death.
While this case series is very limited with its small sample size and lack of evidence if
the nasal packings were the exact cause, it highlights the importance of the occurrence of
identifying the TCR and treating it appropriately.
In a case study published by Klumpp, Jorge, and Azix-Sultan (2013), a 2-year-old
presenting with RB in his right eye was referred for IAC using melphalan. After general
anesthesia was induced, the patient was given muscle paralysis, intubated, and ventilated using
pressure-controlled ventilation. Sevoflurane was used to maintain general anesthesia, mixed with
50% oxygen and air. After his femoral artery was cannulated, a microcatheter was advanced
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through the internal carotid artery and into the ostium of the ophthalmic artery. Two minutes
later, the patient's end-tidal CO2 decreased by 14 mmHg and the patient experienced a
precipitous fall in his oxygen saturation to a nadir of 40%. The anesthesia provider alerted the
neuroradiologist who withdrew the catheter and the patient was ventilated with 100% oxygen.
Wheezing was not heard upon auscultation. After four minutes, end-tidal measurements returned
to normal, but the patient became hypotensive and phenylephrine (2 mcg/kg) was administered
along with a fluid bolus over 30 minutes. Once the patient was stabilized the neuroradiologist
was able to continue with the procedure without any further adverse events.
While there was no discussion of the adequacy of tidal volume administration during the
time of this hemodynamic instability, the decrease in end-tidal CO2 is indicative of dead space
ventilation (Klumpp, Jorge, and Azix-Sultan, 2013). The patient was noted to become
tachycardic, not bradycardic as previous other studies have mentioned. And therefore, we cannot
say that this patient experienced the trigemino-cardiac reflex. Klumpp et al. (2013) continue to
account that in their series of case studies evaluating this phenomenon, it occurred among 8 out
of 30 patients of which experienced similar responses. Not one of their patients ever became
bradycardic and therefore the TCR cannot be blamed.
This literature does not support that the TCR is what occurs during IAC. Based on the
research conducted for this paper, it seems that bradycardia associated with IAC is directly
related to an inability to ventilate, causing hypoxia, and resulting in bradycardia. So why is the
TCR being blamed? And if it is not the TCR causing these symptoms, then what is?
Unfortunately, the afferent and efferent signaling for this phenomenon has not been established,
and the reason as to why this happens remains unknown.
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Diving Reflex
Another autonomic reflex that may explain this cardiorespiratory event, is the diving
reflex. Out of all the research conducted for this literature review, the diving reflex was only
briefly mentioned by Scharoun et al. (2017). Most mammals have an intact diving reflex. It
triggered by immersion of the face in cool
water and is a protective mechanism to
prevent aspiration while underwater. This
reflex results in bradycardia, apnea, and
peripheral vasoconstriction. While
bradycardia occurs with immersion, alone, it
is even further exaggerated by simultaneous
apnea. This reflex is mediated by the
ophthalmic branch of the fifth cranial nerve,
or trigeminal nerve, via the anterior ethmoid
nerve (Scharoun et al., 2017.) Studies
mentioned by Scharoun et al. (2017) have
found that direct stimulation of the anterior
ethmoid nerve in muskrats causes bradycardia, hypotension, and apnea. This pathway can be
seen in Figure 5. Interestingly, cutting the anterior ethmoid nerve completely abolishes the apnea
triggered by nasal stimulation. According to Scharoun et al. (2017), anesthetized and
spontaneously breathing dogs experience a decrease in dynamic lung compliance from 25.5 to
13.7 mL/cm H2O and decrease in heart rate when given intranasal capsaicin. Could this be what
is occurring in patients undergoing IAC for RB? It is unclear. It is also not mentioned in any
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other literature related to IAC for RB, except for the case report by Scharoun et al. (2017). More
research is needed to determine if this is the cause of the sudden cardiorespiratory event during
IAC for RB.
Anesthetic Influence
The previously mentioned studies all conclude that a decrease in respiratory compliance
does indeed occur during ophthalmic artery chemotherapy for RB. It is presumed this is due to
some sort of autonomic reflex, but the exact mechanism remains unclear. None of these studies,
however, have evaluated what anesthetic factors may attribute to this occurrence. In a
prospective, observational, single-arm study by Nghe et al. (2018), the authors hypothesized that
the level of anesthetic depth may influence the occurrence of this respiratory phenomenon. A
total of 115 procedures were analyzed on 32 patients. Other variables, including age and weight,
medical history of asthma or upper respiratory tract infection within four weeks, and exposure to
secondhand smoke were also assessed in hopes to find a possible association with severe
intraoperative cardiopulmonary events.
Nghe et al. (2018) defined severe cardiorespiratory events as arterial hypotension,
bradycardia, and a severe decrease in lung compliance. Out of the 115 procedures, 24 resulted in
adverse cardiorespiratory events—20 experienced a severe decrease in lung compliance, one
experienced bradycardia, and arterial hypotension was seen in nine procedures. All events
occurred within two minutes of catheter insertion into the ophthalmic artery with a median
occurrence of one minute. No events occurred while the catheter was in the carotid artery or after
chemotherapy injection. For patients that experience a severe decrease in lung compliance, their
peak inspiratory pressures gradually rose within the first minute of catheter insertion. Following

ANESTHETIC IMPLICATIONS OF INTRAARTERIAL CHEMO

30

this rise, oxygen saturation decreased and some experienced hemodynamic instability (Nghe et
al., 2018).
Unfortunately, none of the demographic data or medical history was significant in
association with serious adverse cardiorespiratory events. Furthermore, all patients were
maintained under general anesthesia using sevoflurane with mean alveolar concentration (MAC)
values between 1.5 and 1.7, high enough to blunt autonomic reflexes. Patients also received a
bolus of sufentanil 0.2 mcg/kg on induction and additional boluses of 0.1 mcg/kg after femoral
artery puncture. Their bispectral index (BIS) was maintained between 40-50, a value
encouraging of adequate depth of general anesthesia (Nghe et al., 2018).
Nghe et al. (2018), concluded that neither demographic values nor medical history can
predict the occurrence of severe cardiorespiratory events during ophthalmic artery
chemotherapy. Furthermore, this phenomenon can occur despite an adequate depth of general
anesthesia, in which autonomic reflexes should be attenuated.
Treatment of Intraoperative Decrease in Pulmonary Compliance During IAC for RB
While the actual physiology of what causes the decrease in pulmonary compliance during
IAC for RB is unknown, the treatment of possible physiological mechanisms will be discussed. It
is speculated that patients may develop acute bronchospasm due to stimulation of the ophthalmic
artery, causing a decrease in respiratory compliance due to the TCR. This causes a release of
acetylcholine on the muscarinic receptors on the bronchial smooth muscle, resulting in
bronchoconstriction. However, studies have documented the lack of wheezing heard upon
auscultation and furthermore the administration of bronchodilators, like albuterol, do not
improve symptoms. Pediatric intraoperative bronchospasm has an occurrence rate of 0.2-4.1% in
the general population. There are three major triggers for perioperative bronchospasm including
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mechanical airway manipulation, anaphylactoid reactions, and immunological anaphylaxis.
Treatment includes reducing the level of stimulus, deepening the anesthetic, and administration
of 100% oxygen. Pharmacologic intervention includes the administration of beta-2 agonists like
albuterol. If severe airflow limitation persists, intravenous beta-2 agonists like salbutamol and
epinephrine can be administered. Other medications include atropine, glycopyrrolate, and
magnesium, all of which may provide further bronchodilation. Anesthesia providers should do
their best to provide protective lung ventilation and avoid high peak airway pressures to avoid
hyperinflation and barotrauma (Regli & von Ungern-Sternberg, 2015).
Anesthetic Management of Patients with RB
Some level of sedation or general anesthesia is needed for the large array of treatment
options for RB. Therefore, anesthesia providers are becoming more involved in the care of
patients with RB as IAC is becoming a more frequently used treatment option for these patients.
Not only do anesthesia providers need to be well versed in the physiology of the disease but they
also need to well-educated on the potential complications that can occur intraoperatively. The
decrease in pulmonary compliance associated with ophthalmic artery cannulation is well
reported with occurrence rates of 24-29%. Anesthesia providers should anticipate this event to
occur with every anesthetic provided for IAC for RB and have the available tools to treat these
patients readily available.
The Johns Hopkins Hospital IAC for RB and Pediatric Anesthesia
At The Johns Hopkins Hospital in Baltimore, Maryland, IAC is a commonly
administered treatment for RB. Pediatric anesthesia providers are well educated on the disease
and pulmonary manifestations that may occur during the procedure. Dr. Monica Pearl is a
neuroradiologist at JHH and administers IAC to this patient population. From an anecdotal
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perspective, Dr. Pearl discusses the decrease in pulmonary compliance that occurs during this
procedure during her “time out”. She instructs the anesthesia provider to immediately let her
know if this event occurs so that she can retract the cannula from the ophthalmic artery and halts
the procedure until the patient recovers. Anesthesia providers prepare a syringe of epinephrine
diluted to 10 mcg/ml and are prepared to administer it immediately if this event occurs. All
patients are maintained under general anesthesia with sevoflurane and maintain muscle paralysis
with rocuronium. Mechanical ventilation is supported with pressure support ventilation so that if
there is a decrease in pulmonary compliance, the anesthesia provider can be immediately alerted
when there is a decrease in tidal volume. This open line of communication between the
proceduralist and the anesthesia provider ensures that everyone in the room is educated and
prepared for this intraoperative event and have the ability to treat it immediately. This is exactly
what Dr. Monica Pearl does during her “time out.”
Conclusion
RB is a difficult diagnosis for a family to deal with. New therapies like IAC provide
treatment options that are just as effective as intravenous chemotherapy with far fewer side
effects. While these patients do not suffer from the nephrotoxicity, hepatotoxicity,
cardiomyopathy, ototoxicity, and myelosuppression associated with intravenous chemotherapy,
it is far from a benign procedure. The intraoperative cardiorespiratory event associated with IAC
can be devastating. However, it can be anticipated by anesthesia providers and treated
effectively. This can only be attainable by educating the anesthesia provider on how to prepare,
anticipate, identify, and treat this event effectively.
While the exact mechanism that causes such profound cardiorespiratory event during
IAC for RB is not fully known, it is important for the anesthesia provider to be aware that its
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occurrence is a possibility. Further research should be aimed at identifying risk factors for
developing this adverse event as well as the impact of the anesthetic provided. Furthermore, if
this is an autonomic mechanism, research should be aimed at identifying the afferent and efferent
limbs. In the meantime, providers should be aware that when the event does occur, it is prudent
to have an open line of communication with the neuroradiologist. When the catheter
manipulation is stopped, the symptoms usually resolve. As always, patients’ hemodynamics
should be supported by the anesthesia provider throughout the case, and emergency medications
should always be available.
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